EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression

BACKGROUND: The ATLANTIC trial reported that higher PD-L1 expression in tumors was involved in a higher objective response in patients with EGFR(+)/ALK(+) non-small cell lung cancer (NSCLC), indicating the possibility of anti-PD-1/PD-L1 therapy as a third-line (or later) treatment for advanced NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Shunli, Wang, Rong, Zhang, Xiaojuan, Ma, Yueyun, Zhong, Longhui, Li, Ke, Nishiyama, Akihiro, Arai, Sachiko, Yano, Seiji, Wang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864970/
https://www.ncbi.nlm.nih.gov/pubmed/31747941
http://dx.doi.org/10.1186/s12943-019-1073-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864970/
https://www.ncbi.nlm.nih.gov/pubmed/31747941
http://dx.doi.org/10.1186/s12943-019-1073-4

Ejemplares similares